A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

NCT05664243 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Autologous genetically modified gamma-delta T cells
BIOLOGICAL: Allogeneic genetically modified gamma-delta T cells

Sponsor

In8bio Inc.